Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2024-07-28 Governance Information
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
关于拟修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the proposed amendment to the company's Articles of Association (《公司章程》) due to a reduction in registered capital following a share repurchase and cancellation related to a restricted stock incentive plan. It includes details of the changes in share capital and references a board resolution. The document does not contain financial statements or detailed financial analysis, nor is it a full report. It is a regulatory announcement about corporate governance changes, specifically amendments to the company's charter, which is a governance-related matter. The document is relatively short (976 characters) and is not a report publication announcement. Therefore, the most appropriate classification is Governance Information (CGR).
2024-07-28 Chinese
关于召开2024年第二次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 100% confidence The document is a notice announcing the convening of the 2024 second extraordinary general meeting of shareholders (临时股东大会) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), eligibility, agenda items (such as capital reduction and amendment of the company charter), registration procedures, and contact information. There is no financial data, earnings information, or detailed report content. The document is a formal announcement of a shareholders meeting rather than the meeting materials or results. It is not a full report like an Annual Report or Interim Report, nor is it a voting result announcement. The document length is short (2351 characters), and it serves as a meeting notice. Therefore, the appropriate classification is AGM Information (AGM-R).
2024-07-28 Chinese
关于2021年限制性股票定向回购股份方案的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the repurchase and cancellation of restricted shares under the 2021 restricted stock incentive plan. It details the board and shareholder meeting approvals, the basis and price for the repurchase, the number of shares involved, and the impact on share capital and equity structure. The document is a formal announcement about a share repurchase related to an equity incentive plan, including specifics on the repurchase price, shares involved, and legal compliance. It is not a full financial report, earnings release, or management discussion, but rather a specific update on a share repurchase transaction. Therefore, it fits best under the category of Transaction in Own Shares (POS). The document length is 4133 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2024-07-28 Chinese
第四届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results on various proposals related to stock incentive plans, stock repurchase, and termination of a specific stock issuance. The document does not contain financial statements or detailed financial analysis but rather the official decisions and voting outcomes of the Supervisory Board meeting. It is not an Annual Report, Interim Report, or Earnings Release. It is also not a full AGM Information document but rather a meeting resolution announcement. The closest fitting category is Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies. The document is short (1353 characters) and focused on board resolutions, so it is not a report publication announcement or regulatory filing fallback. Therefore, the classification is MANG with high confidence.
2024-07-28 Chinese
第四届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the sixth meeting of the fourth board of directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references to related announcements published on the Beijing Stock Exchange website. The content focuses on board decisions such as stock incentive plans, share repurchases, capital reduction, amendments to the company charter, and convening a shareholders meeting. There is no financial data, earnings information, or detailed report content. The document is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (2234 characters), and it is not a report publication announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2024-07-28 Chinese
开源证券股份有限公司关于江苏德源药业股份有限公司2021年限制性股票激励计划第三个解除限售期解除限售条件成就及回购注销部分限制性股票事项的核查意见
Regulatory Filings
2024-07-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.